Obesity has been associated with poor breast cancer prognosis, however most studies have focused on body mass index (BMI) and few have considered the distribution of adipose tissue. We investigated associations between prediagnostic adiposity and breast cancer survival, considering BMI, waist and hip circumferences (WC and HC), and waist-to-hip ratio (WHR).
Breast cancer is the most prevalent cancer in women in both developed and developing countries. 1 With 5-year relative survival rates of 80% or more in developed countries, 2 an increasing number of women are currently living with a diagnosis of breast cancer. For these cancer survivors, it is essential to identify modifiable risk factors that could influence their prognosis. Breast cancer characteristics such as TNM stage, lymph node status, tumor size, tumor grade, histological type, lymphatic and vascular invasion, hormone receptor and HER2 status, and age at diagnosis are known predictive or prognostic factors. 3, 4 A recent meta-analysis conducted by the World Cancer Research Fund (WCRF) has shown that obesity and excess weight before diagnosis were associated with increased mortality (from all causes and from breast cancer). 5 However, the WCRF expert panel judged that the level of evidence for the association between a healthy body mass index (BMI) and a better survival was only limited, despite suggestive evidence. 6 Weaknesses have been underlined in observational studies as well as in clinical trials. In particular, cohort studies need to assess more systematically important prognostic factors, such as tumor characteristics, treatment or time period of cancer diagnosis (because of rapid changes in treatments). On the other hand, results from clinical trials, which often include such information, do not sufficiently take into account lifestyle factors and are more difficult to generalize because of selection bias in the survivors participating in clinical trials compared with the overall population of survivors. In addition, most published studies have considered only BMI, an overall measurement of adiposity. They rarely considered waist and hip circumferences (WC and HC) or waist-to-hip ratio (WHR), 7 measures of abdominal or gluteofemoral adiposity, which may have a different impact on health than overall adiposity (BMI), 8, 9 in particular with respect to cancer risk. 10 In this context, our objective was to study the associations between several measurements of prediagnostic adiposity (BMI, WC, HC, WHR) and breast cancer survival, overall and in breast cancer subtypes, accounting for major potential confounders, using data from the large E3N prospective cohort study.
Methods
The E3N cohort study
The "Etude Epid emiologique auprès des Femmes de la Mutuelle G en erale de l'Education Nationale" (E3N) study is a prospective cohort study initiated in 1990. 11 Overall, 98,995
women aged 40-65 years were recruited from a national health insurance plan covering mostly teachers. All women gave informed consent, in compliance with the rules of the French National Commission for Data Protection and Privacy, the organization that gave ethical approval for the study. Follow-up questionnaires have been sent every 2-3 years to the participants since 1990, collecting data about lifestyle and reproductive factors as well as major health events, including cancer.
Outcome assessment
Any new diagnosis of cancer event (primary tumors and loco-regional or distant recurrences) reported every two to three years in each follow-up questionnaire up to December 7, 2011 was systematically investigated and validated using pathological reports collected from the patients or their doctors. Tumor characteristics such as stage, grade, nodes, distant metastases, size of the tumor, hormonal receptor status and histological subtype were extracted from pathological reports or any other medical document (such as bone-scan, magnetic resonance imaging (MRI) or X-ray radiography reports). We considered three outcomes after primary invasive breast cancer: second invasive cancer events, deaths from breast cancer and deaths from any cause. We considered as second invasive cancer events loco-regional invasive recurrences, distant recurrences (metastases) or a second invasive cancer of any primary sites up to December 2011. All cancer events diagnosed within a same three-month period were considered as synchronous events. [12] [13] [14] [15] The participants' vital status was regularly updated through the health insurance plan, postal service and next-ofkin; causes of death were obtained from the French National Service on Causes of Death. When breast cancer was reported as the initial cause of death at least 2 years after the initial breast cancer diagnosis without any cancer event reported since the breast cancer diagnosis (N 5 17), we considered that the participant had suffered distant recurrence 2 years before death. These 2 years correspond to the median survival time for women of the study population diagnosed with metastases, and have also been used in similar cohort studies. 16 When time between breast cancer diagnosis and death from breast cancer was <2 years (N 5 21), the date of distant recurrence was defined as the date of death. 16 
Anthropometric measurements
Each follow-up questionnaire asked women to provide their weight in kilograms. Height (cm) was collected in 1990, 1995 and in all questionnaires since 2000. BMI was then computed according to the weight reported in each questionnaire as
Women were asked to report their waist and hip circumferences according to precise instructions in the 1995, 2002 and 2005 questionnaires. 17 Waist circumference was defined as the smallest circumference between the base of the ribs and the largest point of the iliac crest, and hip circumference as the largest circumference below the umbilicus. Waist-tohip ratio was then computed as waist circumference/hip circumference.
Study population
Only women with no personal history of cancer, except basal cell skin carcinoma, prior to breast cancer diagnosis, and whose first primary invasive breast cancer had been
What's new?
If you're fat, you're less likely to survive breast cancer-but does it matter where that fat is on your body? Perhaps, according to a new report. These authors noted that previous work only considers the patient's BMI when studying prognosis. This study tested hip and waist circumference as well. They discovered that women with larger hip circumference had greater risk of death from all causes and from breast cancer, and of second invasive cancer than had women with smaller hips. No association was found with waist circumference or BMI, suggesting there's more to the story than BMI when it comes to cancer survival.
confirmed by a pathological report before June 25, 2008 (N 5 5991, 93.5%), were included in the study. We excluded women with incomplete date of any cancer event or death (N 5 133), in situ breast cancer (n 5 760), phyllode tumors or tumors with missing morphological codes (n 5 7), or metastatic disease at diagnosis (n 5 39). In addition, participants who had no data on BMI, WC or HC before their first primary breast cancer diagnosis were excluded (N 5 1,892). The study population included 3160 cancer cases diagnosed between 1995 (first available data on WC and HC) and June 25, 2008 (date when the validation of first cancer cases was considered complete).
Statistical analyses
Survival follow-up started at the date of diagnosis of the first primary invasive breast cancer. We defined invasive diseasefree survival (iDFS) as time to second invasive cancer event or death from any cause, overall survival (OS) as time to death from any cause and breast cancer-specific survival (BCSS) as time to death from breast cancer, as recommended by Hudis et al. 12 and Gourgou-Bourgade et al. 18 For OS and BCSS analyses, women were followed until the event of interest or until December 7, 2011. Women who did not answer the last questionnaire (11.0%) were considered lost to followup in the iDFS analyses, and censored at the date of the last completed questionnaire plus 6 months. Otherwise, women were followed until the date of diagnosis of a second invasive cancer event, or the first date between date of death, or December 7, 2011 Cox proportional hazards models with time since diagnosis (in months) as the timescale were used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) associated with categories of anthropometric measurements (WHO categories for BMI, and tertiles for HC, WC and WHR), using the last anthropometric measurements available before diagnosis of the first primary invasive breast cancer. Proportional hazards assumption was assessed using log-log plots. For tests of linear trend across categories, we assigned participants the median value for each anthropometric measurement category and modeled the corresponding variable as a continuous term.
Model 1 was adjusted for age at diagnosis, time between exposure assessment and diagnosis, tumor characteristics (Scarff-Bloom-Richardson (SBR) grade of the tumor, estrogen receptor (ER) status, progesterone receptor (PR) status, TNM stage, histological subtype), as well as for hormonal and lifestyle factors at diagnosis: menopausal status, age at menopause, use of menopausal hormone therapy (MHT), use of oral contraceptives, parity, history of benign breast disease, family history of breast cancer in first-degree relatives, smoking status, education level, diabetes and total physical activity in 1990 (MET h/week). HER2 status was available only for 266 women, thus it was not included in the analyses. Mutual adjustments for WC and BMI were added in model 2. All models were stratified according to period of diagnosis (1995-1999; 2000-2004; 2005-2008) .
Adjustments for dietary factors such as daily energy and alcohol intakes in 1993 were examined on the sub-population (N 5 2822) for which dietary intake data were available, after exclusion of subjects with extreme energy intakes. Since estimates remained similar, dietary variables were not included in the final models. For covariates with <5% missing values, missing values were imputed to the modal category or the median value. For SBR grade and hormone receptor status, we created a missing category.
Analyses were further stratified according to TNM stage (stage I or stage II-III), menopausal status at diagnosis (premenopause or postmenopause), ER/PR status and period of diagnosis (before or after 2000).
Sensitivity analyses were performed excluding women with a BMI <18.5 kg/m 2 (n 5 76, 2.4%), women whose last available BMI measurement was reported over 2 years before diagnosis (n 5 1017) and excluding women whose second event was not confirmed by medical document (n 5 135). All statistical tests were two-sided, and p values below 0.05 were considered statistically significant. All analyses were performed with the Statistical Analyses Systems (SAS) version 9.3 (SAS Institute, Cary, NC).
Results
In our study population, 286 women had died before December 2011, of whom 188 because of their breast cancer (among which 130 were stage II or III), and 614 experienced a second invasive cancer event, either loco-regional invasive recurrence (N 5 183), distant metastasis (N 5 211), second primary invasive tumor (N 5 112), uncertain whether primary tumor or metastatic disease (N 5 3) or unclassified cancer event without any pathological report (N 5 105). Overall, 78% of second events were confirmed by a medical document (pathological or medical imaging reports, death certificate).
Mean follow-up was 9.1 years for OS and BCSS, and 8.0 years for iDFS (Table 1) . Mean age at diagnosis was 61.5 years and most cases (90.8%) were diagnosed after menopause. Breast cancer cases were mostly ductal (72.5%), TNM stage I (63.5%), well or moderately differentiated (82.5% SBR grade 1 and 2), and, for tumors with known hormone receptor status, ER positive (82.7%) and PR positive (64.5%). Mean BMI before diagnosis was 23.8 kg/m 2 (WC: 78.6 cm, HC: 98.3 cm, WHR: 0.80) and was assessed on average 19.2 months before diagnosis. Obese and overweight women had a higher prevalence of hormone receptor positive tumors and were older at diagnosis. Obese and overweight women were less likely to have used oral contraceptives or menopausal hormone therapy, and were more often diabetics.
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Abbreviations: OS: overall survival; iDFS: invasive disease free survival; HR: hazard ratio; CI: confidence interval; BMI: body mass index. Table 4 . Associations between anthropometric variables before diagnosis and overall mortality and iDFS after breast cancer according to estrogen and progesterone receptor status of the tumors in the E3N cohort Table 5 . Associations between anthropometric variables before diagnosis and overall mortality and iDFS after breast cancer according to year of diagnosis in the E3N cohort No significant heterogeneity was observed by ERPR status in HC associations although the association with OS seemed stronger in ER2PR2 than in ER 1 PR1 (Model 2: ER 1 PR1 HR >100vs < 95 cm 5 1.94, CI 5 1.02-3.67, P trend 5 0.02; ER2PR2 HR >100vs < 95 cm 5 4.29, CI 5 1.46-12.59, P trend 5 0.01 2 P interaction 5 0.07) ( Table 4) .
When stratifying analyses according to year of diagnosis (Table 5) , we observed a significant interaction for the association between HC and OS (P interaction 5 0.02). Although going in the same direction, associations were stronger in cases diagnosed in 2000 or after compared to cases diagnosed in 1995-1999 ( Model 2, 1995 Model 2, -1999 No statistically significant interaction with menopausal status at diagnosis was observed (Supporting Information Table  1 ), although our population was mostly postmenopausal and very few events were identified in premenopausal cases.
Excluding women with BMI < 18.5 kg/m 2 in sensitivity analyses did not change the associations between HC and OS, BCSS or iDFS. Similarly, the associations between HC and OS, BCSS and iDFS were of the same magnitude when analyses were restricted to women whose last available BMI was within the 2 years before diagnosis, or to women whose last available BMI was more than one year before diagnosis. Excluding women whose second cancer event had not been validated by a pathological report did not modify the association between HC and iDFS. Lastly, excluding breast cancer cases diagnosed during the last 5 years of follow-up did not alter the findings (data not shown).
Discussion
In this prospective cohort of relatively lean women, BMI, WC and WHR were not associated with survival after breast cancer. However, women with a prediagnostic HC > 100 cm were at increased risk of death (from all causes and from breast cancer) and second invasive cancer event, compared to those with HC <95 cm, especially when BMI was adjusted for.
In 15 out of 22 published studies, BMI-defined obesity compared to normal weight was associated with increased risk of death from any cause, and in 14 of them, it was also associated with breast cancer-specific mortality. 5, 20 However, overweight, defined as BMI 25-30 kg/m 2 , was not associated with all-cause mortality in any individual study, and the meta-analysis showed a modest increase in mortality (OS: RR overweight VS normal 5 1.07 (1.02-1.12)). 5 Thus, the absence of an association between BMI and survival in our study could be explained by the low number of obese women (average BMI: 23.7 kg/m 2 , 6% of obese women), and is in agreement with the no or modest associations observed between overall adiposity and survival in the overweight (25-30 kg/m 2 ) BMI range. Regarding the association between prediagnostic BMI and risk of breast cancer recurrence, reports in the literature were inconsistent, with either positive 21, 22 or null 16, 23, 24 associations. There were only two previous studies on WC in relation to events in breast cancer survivors, and they found no association with survival. 20, 25 To our knowledge, only one study 25 investigated associations between prediagnostic HC and risk of death after breast cancer, on a reduced number of postmenopausal women (n 5 698; 56 deaths), and reported a nonstatistically significant increase in risk of death. Postdiagnostic HC was not associated with overall survival in two studies. 26, 27 Our results regarding stage of disease showed no interaction or overlapping confidence intervals, and are consistent with existing data. Some studies suggested that the associations of obesity with breast cancer were either stronger or similar among early stage cancer cases, regardless of the time obesity was assessed. 16, [28] [29] [30] Thus, Majed et al. 29 hypothesized that adiposity would play a stronger role in prognosis when other prognostic factors are more favorable.
In published meta-analyses the ER status did not modify the associations between adiposity and breast cancer survival, 5, 31 although in one meta-analysis 5 prediagnostic BMI was associated with total and breast cancer mortality only in hormone receptor positive cases.
The literature regarding menopausal status at diagnosis is conflicting, however, two recent meta-analyses concluded that no significant difference was observed in the association between prediagnosis BMI and total and breast cancerspecific mortality between pre and postmenopausal women. 5, 31 Excess adiposity has been associated with several metabolic and hormonal dysregulations that involves sex hormones, insulin and insulin-like growth factors or inflammation pathways and adipocytokines. 32 Evidence toward mechanisms involving insulin was considered the strongest by Niraula and Goodwin. 31, 33 However, central adiposity (high WC) is usually more strongly correlated with insulin levels than HC, 34 and our data showed little association of WC with survival. Gluteo-femoral/subcutaneous adiposity, for which HC is a marker, 35, 36 is characterized by the secretion of leptin, 34, 37, 38 an adipocytokine with proangiogenic and anti-apoptotic properties. 39 Interestingly, hyperleptinaemia has already been related to poor prognosis after breast cancer. 40 However, further investigation is needed regarding properties of the gluteo-femoral adipose tissue and its secreted products. 36 Strengths of our study include the prospective design of the E3N cohort study, with regularly updated information, which allowed us to collect anthropometric data from women before their cancer diagnosis, avoiding potential recall bias caused by retrospective assessment at cancer diagnosis. Moreover, first breast cancer cases, and most second events were confirmed by pathological reports, and detailed tumor characteristics were extracted from the records.
However, the E3N cohort study was not originally designed to study survival. Thus, compared to data from clinical studies, some information on tumor characteristics and treatments were incomplete or missing. As the follow-up period for this study lasted from 1995 to 2011, cancer treatments have evolved, as well as routine evaluation of predictive and prognostic factors such as HER2 status. For this reason, we chose to stratify all our analyses by periods of diagnosis. Another limitation is that anthropometric measurements were not clinically assessed, but self-reported. However, a validation study 18 in a subset of the E3N cohort showed high correlation coefficients (>0.80) between weight, height, hip, waist, bust circumferences and BMI measured by a technician, and those measured by the women. Lastly, the low number of BMI-defined obese women and few events in those women limited the study of the association between obesity and survival.
Conclusions
In conclusion, HC was associated with poorer survival after breast cancer in a population of mostly normal-weight French women, whereas BMI-measured overall adiposity was not. This suggests that overall adiposity, at overweight level, does not influence survival and underlines the interest of going beyond BMI when studying anthropometry with regards to breast cancer survival. Thus, we recommend that further studies consider various anthropometric measurements in order to provide complete information that will help to understand the mechanisms underlying associations between adiposity and survival.
